Phase II trial of preoperatively CDDP/S-1 for patients with clinical stage II(exclusion N0 disease) and Stage IIIA non-small cell lung cancer
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000001928
- Lead Sponsor
- Thoracic Surgery, Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with severe drug allergy 2)Patients with administration of another 5-fluouracil derivative drugs, flucytosine, phenytoin, warfarin sodium 3)Patients with active concomitant malignancy 4)Patients with active severe infection, diarrhea, interstinalparalysis, ileus, uncontrolled diabetes mellitus, uncontrolled angina, myocardial infarction within 6 months from onset, heart failure, other severe complications 5)Patients with active lung disease such as idopathic pulmonary fibrosis, pulmonary emphysema, severe chronic bronchitis, bronchial asthma 6)Patients with uncontrollable psychiatrical complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of regulation factors from lymph node samples usng EBUS-TBNA and relation to radiological, histological response rate after induction chemotherapy
- Secondary Outcome Measures
Name Time Method feasibility, progression free survival, overall survival,and safety